Biomedical Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Pharmacogenomics. 2014 Apr;15(6):845-56. doi: 10.2217/pgs.14.44.
In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic features of electronic medical records and have access to large numbers of patients commonly prescribed drugs. Such programs, if carefully designed, may grow over time and hopefully enhance the collection and interpretation of useful data for the clinical applications of pharmacogenomics testing.
在本报告中，我们回顾了药物警戒在检测上市后药物不良事件中的重要性，以及通过将药物基因组学与药物警戒相结合来开发药物基因组警戒计划的潜力。我们建议在使用电子病历基本功能且可获得大量常用处方药物患者的初级保健系统中开始开发此类计划。如果精心设计，此类计划可能会随着时间的推移而发展，并有望增强对药物基因组学检测临床应用有价值数据的收集和解释。
